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Abstract 
Objectives: To provide an overview of existing social scientific literature on health technology 
assessment (HTA), with a focus on sociology and political science and their subfields. 
Methods: Narrative review of key pieces in English. 
Results: Three broad themes recur in the emerging social scientific literature on HTA: the drivers of 
the establishment and concrete institutional designs of HTA bodies; the effects of institutionalized 
HTA on pricing and reimbursement systems and the broader society; and the social and political 
influences on HTA decisions. 
Conclusions: Social scientists bring a focus on institutions and social actors involved in HTA, using 
primarily small-N research designs and qualitative methods. They provide valuable critical 
perspectives on HTA, at times challenging its otherwise unquestioned assumptions. However, they 
often leave aside questions important to the HTA practitioner community, including the role of culture 
and values. Closer collaboration could be beneficial to tackle new relevant questions pertaining to 
HTA. 
 
 
 
1. Introduction 
This themed section of Value in Health asks why the use of health technology assessment (HTA) in 
healthcare decision-making varies widely across countries. Specifically, the issue is interested in how 
this diversity may be shaped by culture, values and institutions. These are the core topics that social 
scientists have explored extensively in other areas of health policy, such as health care reform1–5, 
rationing/priority-setting6–9, or pharmaceutical regulation10–14. Social science has so far paid less 
attention to HTA, a relatively new phenomenon: in 2003, a paper in Social Science and Medicine 
announced that “Despite its importance in governing the direction of innovation in health care 
delivery, there are hardly any empirical studies of HTA in practice”15. Since then, however, social 
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scientists have been increasingly attentive to HTA, and, as the present themed section demonstrates, 
the HTA community shows considerable interest in input from other disciplines. 
We present a narrative review of the emerging empirical literature on HTA from several social 
scientific disciplines: sociology, political science, and their interdisciplinary subfields such as science 
and technology studies (STS), which is concerned chiefly with the social and political aspects of 
scientific practice and technology design and use, and political sociology / political economy, which 
focus on stakeholders’ interests and strategies. The boundaries between these fields are permeable 
and, in the interest of interdisciplinarity, we avoid dwelling on them. Rather, we present a thematic 
narrative review of the common research questions, methods, and findings of social scientific 
scholarship on HTA. While we do not make any claims to exhaustiveness, this is, to the best of our 
knowledge, the first review of its kind. 
After providing more details on our methods, we summarise the established policy analysis literature 
on HTA developed mostly by health economists and HTA practitioners. We then identify three broad 
themes recurrent in the emerging social scientific literature on HTA: the drivers of the establishment 
and concrete institutional designs of HTA bodies; the effects of institutionalized HTA on pricing and 
reimbursement (P&R) systems and the broader society; and the social and political influences on 
HTA decisions. We conclude with a brief discussion of social scientists’ contributions to the study of 
HTA and suggest research avenues of interest to social science as well as HTA practitioners. 
 
2. Methods 
 
We reviewed key pieces on HTA from sociology, political science and their subfields. Inclusion 
criteria were: English language, mention of “health technology assessment” in the papers’ title or 
abstract, and empirical content in the body of the paper. Given the difficulties of using conventional 
systematic review methods in social sciences, especially for multidisciplinary topics16–18, we 
employed a step-wise quadruple search strategy. The basis for our search was our pre-existing social 
scientific bibliography on HTA, which we had been developing independently since 2010 (e.g.19). We 
 4 
 
then used reference snowballing techniques to identify additional literature, specifically reference 
checking and citation search in Google Scholar18. Next, we searched (in October 2018) Google 
Scholar for keywords associated with key topics emerging from our expanded bibliography (e.g. 
“HTA + uncertainty of evidence” or “HTA + public engagement”). Finally, we searched for these 
terms manually in selected top-ranking journals in health policy, sociology, political science and their 
subfields, namely Sociology of Health and Illness; Social Science and Medicine; Social Studies of 
Science; Minerva; Health Economics, Policy, and Law; Health Policy; and Journal of Health Policy, 
Politics and Law.  
This resulted in a body of 41 references (see Appendix 1), from which we extracted central topics, 
research questions, methodologies and disciplines. Based on the central topics and research questions, 
we inductively identified a set of common broad themes covered by the papers and agreed on their 
relevance through discussion among authors. We paid special attention to dissenting opinions among 
our team which could help us identify dissent within the literature20. We present the results in the form 
of a narrative review, which allows us to juxtapose “diverse forms of evidence” and literatures side by 
side21 – in this case, the established HTA literature, typically written by health economists and other 
HTA practitioners, and the emerging social scientific scholarship. For the purposes of this review, we 
set (health) economics apart from other social sciences, and we also leave aside the important 
contributions of normative political theory and philosophy, as well as of the humanities and the law.  
 
3. Results 
3.1. The established literature on HTA 
Since the early years of HTA in the 1980s, much of HTA scholarship has been made up of 
publications on the methodologies for assessment of health technologies and of evaluations of 
individual technologies, useful to academics and decision-makers. Not far behind were conceptual 
essays on the nature of HTA, its relationships to evidence-based medicine, P&R processes, and 
biomedical research and innovation22–26. HTA has also attracted the attention of philosophers and 
political and legal theorists27–30 and a number of publications documenting its history emerged (31–35). 
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With one possible exception36, a critical history of the rise of HTA as a discipline has yet to be 
written.  
The vast majority of the social science literature is focused on studying HTA as national institutions 
and individual regulatory decisions – the policy analysis of HTA and P&R procedures, mostly written 
by health economists and other HTA practitioners. Health economists have an obvious disciplinary 
claim to HTA: they are the ones developing the necessary methodologies for quantifying and 
comparing value for money of health technologies. They also have a direct interest in understanding 
how their science is applied in practice – in appraisals and funding decisions. As a result, one of the 
three sections of the International Journal of Technology Assessment in Health Care has been since 
2010 called “policies” (in addition to “methods” and “assessments”). Other journals, including Value 
in Health, have devoted special issues to overviews of HTA in selected countries37. The aim of these 
policy analyses is primarily descriptive: to document and compare what methods are used in different 
jurisdictions and how they compare internationally (e.g.38–40). In the rapidly evolving field of HTA, 
where policies change every couple of years, these records from individual countries provide valuable 
information. Insofar as HTA policy analysis has deeper analytical intentions, these are usually 
identifying various “barriers and opportunities” for the establishment, development, or increased use 
of HTA by decision-makers41–43 (with exceptions, e.g.44). In these, political and societal factors are 
typically noted (often as “lack of political will” or “social acceptability” or “institutional capacity”) 
but rarely discussed in detail. Along with other themes, they are, however, central to the social science 
on HTA. 
 
3.2. The emerging social science literature on HTA 
 
The emerging social scientific literature on HTA can be divided according to its three most common 
research themes: the drivers of the establishment and design of HTA bodies; the effects of 
institutionalized HTA on P&R, medical practice, and the broader society; and the social and political 
influences on HTA decisions.  
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3.2.1. What explains variations in how HTA is institutionalized and practiced? 
The first question social scientists ask takes the adoption of HTA as a dependent variable: why are 
HTA bodies established? Conventional wisdom from HTA policy analysis would presume that HTA 
spreads through the world and that, sooner or later, countries without HTA will all create HTA 
agencies as a necessary tool to organise an efficient distribution of limited healthcare resources (e.g. 
45–47). However, some political scientists disagree with the presumption that HTA is inevitable. 
Functional pressures on healthcare can be very different across countries and therefore HTA may be 
promoted by local actors as a solution to very different problems48,49. For example, in Poland HTA 
was presented as a way of complying with EU legislation on pharmaceuticals and defining the basic 
benefit package, while some in the Czech Republic saw HTA as a tool to control spending on medical 
devices and diagnostics50.  
Others agree with the basic premise that HTA diffuses because of a functional pressure on public 
finances but offer important nuance. For example, a series of studies on Sweden, France and 
Germany51–53 claims that “the emergence and continuing function of national [independent agencies] 
for HTA follows a broadly evolutionary pattern” but that within this evolution, “contextual factors 
play an important mediating role”53. What is mediated here are the concrete institutional, 
methodological and procedural aspects of HTA and its relationship to P&R in individual countries.  
These differ starkly, as yet others have noted: no two HTA systems are the same and that none of the 
usual suspects (e.g. geography, GDP, timing of HTA institutionalization) explain this major 
institutional variation54. But institutional context in individual countries may help us understand the 
bodies’ genesis and design. In France, for instance, the national regulatory context (pre-existing 
institutions with their own priorities and mandates) meant that the HTA body received a mandate 
which went well beyond cost-effectiveness analysis to pursue a range of mechanisms for containing 
healthcare spending53. Similarly, the fragmented multi-level nature of Canadian healthcare has 
conditioned the extent and nature of intra-Canadian cooperation of HTA bodies55. Further, conscious 
strategies of key actors may matter: functional pressures or historical administrative traditions of each 
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country may have less influence on what HTA bodies looks like than high politics, such as the left-
right divide56. When given the chance, governments strategically shape the institutional design of 
HTA bodies according to their political preferences57.  
The use of specific methods for appraisal and assessment methods is also conditioned by their 
regulatory context. For instance, the use of the efficiency frontier in HTA in Germany (as opposed to 
cost-effectiveness threshold in the United Kingdom) is argued to be the result of different “regulatory 
spaces”, inhabited by a multiplicity of public, private and non-government actors, value judgements 
and cultural norms, and power dynamics: it is unacceptable in Germany to mention healthcare 
rationing or describe health gains in monetary terms51. In short, context matters for why HTA bodies 
emerge and what they do. 
Finally, some of the empirical social science literature looks at why politicians and policy-makers 
would want HTA in the first place. There are other alternatives to implementing a national HTA 
agency in the P&R toolkit, especially if cost-containment is the goal49. This could include reference 
pricing, reimbursement decision referencing (e.g.58), managed-entry agreements, and delaying or 
preventing market entry to expensive or new therapies. Delegating authority to specialised HTA 
bodies, however, serves multiple purposes for politicians, including creating a pool of experts capable 
of resolving complex problems, but also gaining legitimation by adopting an “evidence-based policy” 
discourse, and avoiding blame in case of controversial decisions49,56,59. Potentially, it also “enhances 
politicians’ capacities to institute their ideological preferences within a set of concrete rules and 
‘expert’ decision making procedures”60. Once established, arm’s-length HTA agencies are shown to 
have significant staying power in the face of efforts to re-politicize decision-making60–62 though not 
full immunity from politics, especially if the political costs are too high or the political calculus itself 
changes exogenously60,63. 
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3.2.2. What are the effects of institutionalized HTA on reimbursement 
decisions and beyond? 
Another strand of empirical social science literature takes the existence and characteristics of HTA 
systems as an independent variable and asks what its consequences are for P&R and broader 
healthcare systems. The transparency and inclusiveness of the assessment and appraisal process are 
among the key aspects of HTA that are theorized to matter for outcomes. Within the established HTA 
literature, health economists have produced a growing body of quantitative analyses examining the 
link between HTA agencies and their often diverging P&R decisions64,65. Differences in 
recommendations are thought to be due to an agency’s approach to risk perception, the comparator 
choice used in clinical and cost-effectiveness studies66, or the drug and disease characteristics67. 
Although countries with similar institutional setup of HTA tend to reach somewhat similar P&R 
decisions, comparable procedural setups (namely, who assesses evidence and when) played an unclear 
role68. “Process configuration”, however, does not seem to have major effects on P&R outcomes – at 
least where evidence about a technology is strong; where evidence is uncertain, the inclusiveness of 
the HTA process (the number of stakeholders involved) increases the likelihood of a positive 
reimbursement decision69.  
Social scientists are similarly on the fence as to the impact of procedural aspects on P&R decisions. A 
large-N analysis of the impact of the design and procedures of HTA institutions (namely their 
transparency, inclusiveness to stakeholders, and consensus / majority voting) found only weak 
statistical evidence for any influence on reimbursement outcome70. A qualitative Hungarian case 
study explains the limited influence of HTA on P&R outcomes by the lack of transparency of the 
HTA process, although other factors (including institutional design, human resources - “brain drain” 
to the private sector, and key actors’ disinterest in reform) were also mentioned71. Recent work on the 
“practical” transparency of HTA bodies71–73 may perhaps contribute to making transparency a better 
defined variable amenable to both qualitative and quantitative inquiry. As STS scholars emphasise, 
procedural choices and guidelines both reflect and result in privileging certain forms of rationality and 
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certain voices and perspectives over others, amplifying or creating new power disparities in the 
process74. 
Critical STS scholars see HTA as actively changing broader socio-political contexts. HTA, alongside 
other types of regulation, influences the very process of innovation, affecting the balance of social 
power by making new alliances possible, as well as by prioritizing or legitimizing particular actors 
and select forms of evidence and interest expression36,75. Most importantly, HTA is both driven by and 
contributing to broader social tendencies, such as the shift toward the medicalization of society, the 
shift toward neoliberal governance and the consolidation of the regulatory state, and the “evolving 
modes” of scientific knowledge production, subsumed under labels such as regulatory science, trans-
science, or post-normal science75. We should note that health economists have recently also started to 
devise empirical strategies to study the broader effects of HTA beyond P&R76. 
Some HTA practitioners have proposed that HTA can complement and enhance evidence-based 
medicine (EBM) by giving doctors and patients information that goes beyond efficacy and 
effectiveness, concentrating on those outcomes that are most relevant and significant to the patient77. 
HTA is intended to influence clinical practice (including prescription practice) through clinical 
guidelines, and patient behavior via publicly available appraisals. Empirical social scientists, and 
especially STS scholars, have, however, challenged whether access to the type of evidence ranked 
highly by HTA impacts clinical behavior in practice78; whether EBM’s impact on clinical behavior is 
a positive development79; and whether what HTA provides is commensurate with what patients 
seek74,80. 
 
3.2.3. How do the social and political contexts affect HTA decision-making?  
A final, broad strand of the social science literature examines how HTA decisions are made in 
practice, within particular social and political contexts. Established HTA literature has been aware of 
the tension between HTA’s technocratic qualities and the political nature of rationing healthcare 
resources62,81 but often treats it as a “barrier to HTA adoption” by decision-makers that can be 
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overcome by improving HTA methods (e.g.82). In contrast, the political science and sociology 
literature takes the politics of HTA as their main focus. It is particularly interested in “backstage 
decision-making”83, which it most often investigates with the help of ethnographic methods such as 
semi-structured interviews, observation, and participation in HTA bodies’ meetings. It frequently 
focuses on “crucial case studies” of often controversial technologies84–86 or studies decision-making in 
individual HTA institutions72,87–89. Two key subtopics emerge from this literature: the interests and 
behaviours of main “stakeholders” and the nature and role of what counts as “evidence” in HTA. 
First, “stakeholder involvement” is an unquestionable normative principle of HTA90, very much in 
line with the current paradigm of (good) governance 91. In this context, stakeholders are quite often 
synonymous with patient advocacy organisations, and much of the HTA policy analysis literature 
seeks to assess (and possibly enhance) their involvement in HTA processes92–97. STS scholars and 
sociologists ask very similar questions: they study the rationale and determinants of patient 
participation, its institutional frameworks, formal and informal modes of involvement, and the 
mechanisms for considering patient contributions98–100.  
The empirical STS literature echoes the HTA analysts’ concerns that patient involvement is, in one 
way or another, limited. In meetings of the English National Institute for Health and Care Excellence 
(NICE), patient voices have been found to have a “symbolic and representative” function, “relegated 
to the periphery of participation”100, reflecting skewed power dynamics between experts and 
patients98. An Australian study found that these power differentials lead patients to strategically align 
with industry to amplify their views during the HTA process101. Quite often, these social scientists 
would agree with HTA practitioners’ premise that more stakeholder (patient) engagement is necessary 
and desirable, although they place a much greater emphasis on informal practices in addition to 
formal rules of participation. 
A more critical take on stakeholder involvement, rooted in political sociology / political economy, 
examines the roles of other actors than patients, including members of appraisal committees, clinical 
experts, policymakers and bureaucrats71,72,102,103. Just like work by established HTA analysts87 and 
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scholars of pharmaceutical regulation10, this literature examines the way various actors attempt to 
“game the system” by biasing or capturing HTA regulators. For instance, several studies of lobbying 
methods deployed by drug manufacturers in Poland to secure favourable HTA outcomes document a 
mixture of universal lobbying strategies, such as endorsements by clinical experts, coupled with 
context-dependent approaches, such as informal clique influence102,103. But manufacturers are not the 
only stakeholders with vested interests in HTA. There are also HTA consultancies assisting the 
industry in developing evidence submissions, who may be interested primarily in creating business for 
themselves, rather than creating or reforming HTA systems71,102, and the “epistemic community” of 
HTA experts, who have potential material or reputational gains from creating and maintaining HTA 
institutions36,50. In addition, politicians and bureaucrats have a strong stake in limiting impact on 
public budgets. This may result in additional pressure on HTA bodies to avoid, delay or impose 
restrictions on positive reimbursement decisions; this influence can be formal86 or informal71.  
Second, an alternative way of considering HTA practice as part of a socio-political context is to shift 
focus from actors to evidence. Close to the STS take on patient involvement, this scholarship asks 
about the forms of expertise and evidence privileged by HTA processes, how they interact and why 
some of them seem to be more influential than others84,98,100. A key conclusion reached by this 
literature points to the limitations on objectivity and rationality in HTA decision-making9,88. The 
question of what counts as evidence is non-trivial – HTA privileges “hard”, quantitative evidence 
conveyed by experts in economics and medicine36,74, while lived experience of practitioners and 
patients is seen as less important100,101,104,105. Rationality is further limited by an issue well-known to 
health economists and other HTA analysts: the uncertainty of evidence. Moving beyond the statistical 
understanding of uncertainty 84, qualitative studies of HTA decision-making see uncertainty as being 
present within the “epistemology, procedures, interpersonal relations, and technicality” of HTA88, 
which result in a decision-making process that is subtly biased. Crucially, the HTA process is 
characterized by a “negotiation with the use of pragmatic methods to navigate through complexity and 
layers of uncertainty”88. With high uncertainty, the scope for rational-comprehensive decision-making 
becomes limited, and is supplemented by decision-making based on other criteria, for instance trust in 
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other stakeholders106. With their focus on formal and informal practices, social scientists thus show 
how far removed concrete processes may be from HTA’s basic promise of purely rational “evidence-
based” policy. 
 
4. Discussion & Conclusions 
 
This paper summarised the growing empirical social science literature on HTA from political science, 
sociology and adjacent (sub)disciplines of STS, political sociology and political economy in a 
narrative review organised around the key themes of the literature. We are conscious of five potential 
biases of this paper. First, we focused on (sub)disciplines with which we are most familiar. Second, 
we considered empirical papers only. Third, we included works that identify health technology 
assessment as their key topic. As a result of these biases, we may have omitted work from other 
empirical disciplines, and we have ignored works from political and social theory and humanities or 
law altogether. We have also excluded closely related social scientific scholarship on priority-setting, 
rationing, reimbursement decisions, or value, which often addresses similar questions to the study of 
HTA. Fourth, we reviewed exclusively works in English, possibly introducing a NICE-bias. While 
this may well be a faithful reflection of the literature107, we may be perpetuating an Anglo-centric 
perspective on the study of HTA to the detriment of alternative views. Fifth, by juxtaposing the social 
scientific literature to the more established HTA policy analysis, we may have inadvertently 
oversimplified existing health economic scholarship.  
We argue that social scientists peer into the black box of “political will”, “barriers and opportunities”, 
“societal values”, or “institutional capacity” that are usually referred to in passing by most of the 
established literature on HTA. Ontologically, the universe social scientists seek to understand 
comprises two sets of entities: institutions/processes (e.g. HTA bodies and approaches) and 
actors/stakeholders (e.g. patient organisations, bureaucrats, manufacturers), which are used 
interchangeably as dependent and independent variables against each other. These two foci are near-
exhaustive, with most topics falling into one of the two categories. For instance, common interests of 
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HTA policy analysis such as transparency or methodology of HTA, are often conceived as 
institutional traits, while topics such as uncertainty of evidence are conceptualised as resulting from 
social construction or negotiation by individual actors.  
This ontological orientation reflects broader trends in sociology and political science since the 1980s, 
namely the ascendance of  new institutionalism, emphasising the role of institutions, defined broadly 
as organizations, norms and practices, in decision-making108,109, and the rise of actor-network theory, 
interested in social mechanisms involved in the operation of networks formed by “human” and “non-
human” actors, such as technologies110 Similarly, the more critical approaches to HTA in our review, 
mainly from political economy and STS, are consistent with major critiques of the capitalist state111–
113, viewing organisations as sites of strategic struggle for resources and control between competing 
social forces. That said, notable from our review is the limited interest of social scientists of HTA in 
the analytical category of culture, including values (with exceptions51). This contrasts, in particular, 
with some areas of medical sociology, in which culture plays a prominent role in explaining how 
organisations deliver patient care114.  
Methodologically, social science studies of HTA tend to emphasise the “depth” of explanation over its 
“breadth”. They tend to study “crucial” single cases or adopt a small-N design based on a limited 
number of key similarities or differences between the studied HTA systems (with exceptions70). These 
studies tend to provide qualitative “thick description”115 of two-way relationships between HTA and 
its social context. While these small-N studies may, in aggregate, help identify broad patterns, their 
ability to provide generalizable answers remains limited by the idiosyncratic and ever-evolving nature 
of national HTA systems.  
What insights, then, can social science offer to HTA practitioners? It is certainly too early to expect, 
as this themed section suggests, an integrated account of the relative role of “culture, institutions and 
values” in many dimensions of HTA. Questions of interest for social scientists as “outsiders” or 
“strangers”116 may also be uncomfortable for those “on the inside”, especially when these questions 
problematize or even challenge some of the key principles of HTA as a science and practice (e.g.: 
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“Can evidence-based, rational decisions be reached under high uncertainty?”, “Is stakeholder 
involvement universally beneficial?”). Compounding the potential frustrations may be fundamental 
differences in disciplinary training between social scientists and HTA practitioners. Here, this division 
could perhaps be overcome via closer collaboration and shared disciplinary understanding (which this 
themed section fosters), similarly to the initially strained but today well-established relationship 
between medicine and medical sociology117. One possible step towards greater collaboration would be 
to incorporate social scientific questions more closely into future HTA research projects. Another 
would be to emphasize social science in HTA curricula.  
A more integrated collaboration could also help address the big question so far neglected by both 
social science and most HTA policy analysis118–120: what is HTA actually good for? Assessing the 
real-world monetary, health and broader societal effects of HTA as currently implemented in 
countries around the world will require the expertise of not only traditional HTA practitioners, but 
also the unique perspectives of social science (as well as the humanities, law and other disciplines). 
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